Given the favorable safety profile of trastuzumab and its efficacy in breast cancer therapy [38, 39] CD340 expression may also be an advantageous single target that could be explored to target TIS HCC cells, but this remains to be verified. Here, ERBB2 is linked to breast carcinoma.